BACKGROUND: Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience a high burden of symptoms and functional impairment, and a poor quality of life. In the STEP-HFpEF trial (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity), once-weekly semaglutide 2.4 mg improved symptoms, physical limitations, and exercise function, and reduced inflammation and body weight. This prespecified analysis investigated the effects of semaglutide on the primary and confirmatory secondary end points across the range of the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at baseline and on all key summary and individual KCCQ domains. METHODS: STEP-HFpEF randomly assigned 529 participants with symptomatic HF, an ejection fraction of ≥45%, and a body mass index of ≥30 kg/m2 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks. Dual primary end points change in KCCQ-Clinical Summary Score (CSS) and body weight. Confirmatory secondary end points included change in 6-minute walk distance, a hierarchical composite end point (death, HF events, and change in KCCQ-CSS and 6-minute walk distance) and change in C-reactive protein. Patients were stratified by KCCQ-CSS tertiles at baseline. Semaglutide effects on the primary, confirmatory secondary, and select exploratory end points (N-terminal pro-brain natriuretic peptide) were examined across these subgroups. Semaglutide effects on additional KCCQ domains (Total Symptom Score [including symptom burden and frequency], Physical Limitations Score, Social Limitations Score, Quality of Life Score, and Overall Summary Score) were also evaluated. RESULTS: Baseline median KCCQ-CSS across tertiles was 37, 59, and 77 points, respectively. Semaglutide consistently improved primary end points across KCCQ tertiles 1 to 3 (estimated treatment differences [95% CI]: for KCCQ-CSS, 10.7 [5.4 to 16.1], 8.1 [2.7 to 13.4], and 4.6 [-0.6 to 9.9] points; for body weight, -11 [-13.2 to -8.8], -9.4 [-11.5 to -7.2], and -11.8 [-14.0 to -9.6], respectively; Pinteraction=0.28 and 0.29, respectively); the same was observed for confirmatory secondary and exploratory end points (Pinteraction>0.1 for all). Semaglutide-treated patients experienced improvements in all key KCCQ domains (estimated treatment differences, 6.7-9.6 points across domains; P≤0.001 for all). Greater proportion of semaglutide-treated versus placebo-treated patients experienced at least 5-, 10-, 15-, and 20-point improvements in all KCCQ domains (odds ratios, 1.6-2.9 across domains; P<0.05 for all). CONCLUSIONS: In patients with HFpEF and obesity, semaglutide produced large improvements in HF-related symptoms, physical limitations, exercise function, inflammation, body weight, and N-terminal pro-brain natriuretic peptide, regardless of baseline health status. The benefits of semaglutide extended to all key KCCQ domains. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04788511.

Baylor Scott and White Research Institute Dallas TX

College of Health and Medicine The Australian National University Canberra Australia

Department of Cardiology Herlev Gentofte Hospital University of Copenhagen Herlev Denmark

Department of Cardiovascular Disease Saint Luke's Mid America Heart Institute University of Missouri Kansas City School of Medicine

Department of Cardiovascular Medicine Mayo Clinic Rochester MN

Department of General Internal Medicine 3 Kawasaki Medical School Okayama Japan

Department of Internal Medicine Sections of Cardiovascular Medicine and Geriatrics Wake Forest University School of Medicine Winston Salem NC

Department of Medicine University of Mississippi Jackson

Diabetes Research Centre University of Leicester and NIHR Leicester Biomedical Research Centre UK

Division of Cardiac Surgery Li Ka Shing Knowledge Institute of St Michael's Hospital Unity Health Toronto University of Toronto ON Canada

Division of Cardiology Department of Medicine Northwestern University Feinberg School of Medicine Chicago IL

Institute for Clinical and Experimental Medicine IKEM Prague Czech Republic

Novo Nordisk A S Søborg Denmark

School of Cardiovascular and Metabolic Health University of Glasgow UK

Ann Intern Med. 2024 May;177(5):JC56. doi: 10.7326/J24-0025. PubMed

See more in PubMed

Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA. 2023;329:827–838. doi: 10.1001/jama.2023.2020 PubMed

Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC Scientific Statement. J Am Coll Cardiol. 2023;81:1810–1834. doi: 10.1016/j.jacc.2023.01.049 PubMed

Morgen CS, Haase CL, Oral TK, Schnecke V, Varbo A, Borlaug BA. Obesity, cardiorenal comorbidities, and risk of hospitalization in patients with heart failure with preserved ejection fraction. Mayo Clin Proc. 2023;98:1458–1468. doi: 10.1016/j.mayocp.2023.07.008 PubMed

Dalos D, Mascherbauer J, Zotter-Tufaro C, Duca F, Kammerlander AA, Aschauer S, Bonderman D. Functional status, pulmonary artery pressure, and clinical outcomes in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2016;68:189–199. doi: 10.1016/j.jacc.2016.04.052 PubMed

Kitzman DW, Shah SJ. The HFpEF obesity phenotype: the elephant in the room. J Am Coll Cardiol. 2016;68:200–203. doi: 10.1016/j.jacc.2016.05.019 PubMed

Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136:6–19. doi: 10.1161/CIRCULATIONAHA.116.026807 PubMed PMC

Reddy YNV, Lewis GD, Shah SJ, Obokata M, Abou-Ezzedine OF, Fudim M, Sun JL, Chakraborty H, McNulty S, LeWinter MM, et al. . Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study. Mayo Clin Proc. 2019;94:1199–1209. doi: 10.1016/j.mayocp.2018.11.037 PubMed

Reddy YNV, Rikhi A, Obokata M, Shah SJ, Lewis GD, AbouEzzedine OF, Dunlay S, McNulty S, Chakraborty H, Stevenson LW, et al. . Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity. Eur J Heart Fail. 2020;22:1009–1018. doi: 10.1002/ejhf.1788 PubMed

Adamson C, Kondo T, Jhund PS, de Boer RA, Cabrera Honorio JW, Claggett B, Desai AS, Alcocer Gamba MA, Al Habeeb W, Hernandez AF, et al. . Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur Heart J. 2022;43:4406–4417. doi: 10.1093/eurheartj/ehac481 PubMed PMC

Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res. 2023;118:3434–3450. doi: 10.1093/cvr/cvac120 PubMed PMC

Reed SD, Fairchild AO, Johnson FR, Gonzalez JM, Mentz RJ, Krucoff MW, Vemulapalli S. Patients’ willingness to accept mitral valve procedure-associated risks varies across severity of heart failure symptoms. Circ Cardiovasc Interv. 2019;12:e008051. doi: 10.1161/CIRCINTERVENTIONS.119.008051 PubMed

Forman DE, Arena R, Boxer R, Dolansky MA, Eng JJ, Fleg JL, Haykowsky M, Jahangir A, Kaminsky LA, Kitzman DW, et al. ; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council. Prioritizing functional capacity as a principal end point for therapies oriented to older adults with cardiovascular disease: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2017;135:e894–e918. doi: 10.1161/CIR.0000000000000483 PubMed PMC

Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant. 2001;20:1016–1024. doi: 10.1016/s1053-2498(01)00298-4 PubMed

Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Møller DV, et al. . Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069–1084. doi: 10.1056/nejmoa2306963 PubMed

Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Christensen L, Davies M, Hovingh KG, Kitzman DW, Lindegaard ML, Møller DV, et al. . Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype. JACC Heart Fail. 2023;11:1000–1010. doi: 10.1016/j.jchf.2023.05.010 PubMed

Kosiborod MN, Bhatt AS, Claggett BL, Vaduganathan M, Kulac IJ, Lam CSP, Hernandez AF, Martinez FA, Inzucchi SE, Shah SJ, et al. . Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol. 2023;81:460–473. doi: 10.1016/j.jacc.2022.11.006 PubMed

Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35:1245–1255. doi: 10.1016/s0735-1097(00)00531-3 PubMed

Joseph SM, Novak E, Arnold SV, Jones PG, Khattak H, Platts AE, Dávila-Román VG, Mann DL, Spertus JA. Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction. Circ Heart Fail. 2013;6:1139–1146. doi: 10.1161/circheartfailure.113.000359 PubMed PMC

Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J Am Coll Cardiol. 2020;76:2379–2390. doi: 10.1016/j.jacc.2020.09.542 PubMed

Borlaug BA, Kitzman DW, Davies MJ, Rasmussen S, Barros E, Butler J, Einfeldt MN, Hovingh GK, Møller DV, Petrie MC, et al. . Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med. 2023;29:2358–2365. doi: 10.1038/s41591-023-02526-x PubMed PMC

Butler J, Filippatos G, Jamal Siddiqi T, Brueckmann M, Böhm M, Chopra VK, Pedro Ferreira J, Januzzi JL, Kaul S, Piña IL, et al. . Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation. 2022;145:184–193. doi: 10.1161/CIRCULATIONAHA.121.057812 PubMed PMC

Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, Khariton Y, Malik AO, Khumri T, Umpierrez G, et al. . The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27:1954–1960. doi: 10.1038/s41591-021-01536-x PubMed PMC

Wachter R, Shah SJ, Cowie MR, Szecsödy P, Shi V, Ibram G, Zhao Z, Gong J, Klebs S, Pieske B. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Fail. 2020;7:856–864. doi: 10.1002/ehf2.12694 PubMed PMC

Gronda E, Vanoli E, Iacoviello M. The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction. Eur Heart J Suppl. 2020;22:L77–L81. doi: 10.1093/eurheartj/suaa140 PubMed PMC

Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, et al. ; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–1392. doi: 10.1056/NEJMoa1313731 PubMed

Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, et al. ; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089–1098. doi: 10.1056/NEJMoa2206286 PubMed

Sorimachi H, Burkhoff D, Verbrugge FH, Omote K, Obokata M, Reddy YNV, Takahashi N, Sunagawa K, Borlaug BA. Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23:1648–1658. doi: 10.1002/ejhf.2254 PubMed

Reddy YNV, Obokata M, Testani JM, Felker GM, Tang WHW, Abou-Ezzeddine OF, Sun JL, Chakrabothy H, McNulty S, Shah SJ, et al. . Adverse renal response to decongestion in the obese phenotype of heart failure with preserved ejection fraction. J Card Fail. 2020;26:101–107. doi: 10.1016/j.cardfail.2019.09.015 PubMed PMC

Obokata M, Kane GC, Reddy YN, Olson TP, Melenovsky V, Borlaug BA. Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study. Circulation. 2017;135:825–838. doi: 10.1161/CIRCULATIONAHA.116.024822 PubMed PMC

Bertoni AG, Wagenknecht LE, Kitzman DW, Marcovina SM, Rushing JT, Espeland MA; Brain Natriuretic Peptide Subgroup of the Look AHEAD Research Group. Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes. Obesity (Silver Spring). 2012;20:1511–1518. doi: 10.1038/oby.2011.296 PubMed PMC

Verma S, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Petrie MC, Shah SJ, Dhingra NK, Kosiborod MN. A big STEP for treatment of heart failure with preserved ejection fraction. Cell Metab. 2023;35:1681–1687. doi: 10.1016/j.cmet.2023.08.003 PubMed

McEvoy BW. Missing data in clinical trials for weight management. J Biopharm Stat. 2016;26:30–36. doi: 10.1080/10543406.2015.1094814 PubMed

Wang Y, Tu W, Kim Y, Sinks S, He J, Cambon A, Crackel R, Hamilton K, Kettermann A, Clark J. Statistical methods for handling missing data to align with treatment policy strategy. Pharm Stat. 2023;22:650–670. doi: 10.1002/pst.2299 PubMed

See more in PubMed

ClinicalTrials.gov
NCT04788511